Cargando…
Siglecs as Therapeutic Targets in Cancer
SIMPLE SUMMARY: Hyperglycosylated cancer cells are often decorated with abundant sialic acids, which are recognized by Sialic acid binding immunoglobulin type lectins (Siglecs) expressed on immune cells. As sialic acids are normally expressed on almost all cell types, Siglecs can function as recepto...
Autores principales: | Lim, Jackwee, Sari-Ak, Duygu, Bagga, Tanaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615218/ https://www.ncbi.nlm.nih.gov/pubmed/34827170 http://dx.doi.org/10.3390/biology10111178 |
Ejemplares similares
-
Development of Effective Siglec-9 Antibodies Against Cancer
por: Wang, Jun Hui Shawn, et al.
Publicado: (2022) -
Advances in CRISPR-Cas9 for the Baculovirus Vector System: A Systematic Review
por: Sari-Ak, Duygu, et al.
Publicado: (2022) -
Discovery, Function, and Therapeutic Targeting of Siglec-8
por: Youngblood, Bradford A., et al.
Publicado: (2020) -
Current Status on Therapeutic Molecules Targeting Siglec Receptors
por: Lenza, María Pia, et al.
Publicado: (2020) -
Siglec Ligands
por: Gonzalez-Gil, Anabel, et al.
Publicado: (2021)